October 24, 2020

The Niche

Knoepfler lab stem cell blog

Stem cells for COVID-19

5 min read

How can we scientists find ways to keep doing our research during the COVID19 pandemic even if it has nothing to do with the coronavirus? Also, how should those of us involved in science communication talk about the outbreak? At a more basic level, how can scientists try not to go bonkers during this dark time? Patients and scientist patience As I’ve been writing here on The Niche during the pandemic I’ve been aiming to focus on practical issues. For instance, can new cellular …Read More

3 min read

It’s not every day that I call a bunch of stem cell clinics to say “hi”, but yesterday I called some of them during a needed lunch break from grant writing to see what they were doing about their operations during the COVID-19 pandemic. The impetus for this survey of a sort was a question someone asked me last week, “Are stem cell clinics still open during the pandemic? They can’t be, right?” That got me thinking — could these clinics selling injections of …Read More

7 min read

To get at addressing what’s the real deal on the idea of cellular therapies for COVID-19, I did a short email Q&A interview with Dr. Sean Morrison. Sean is Chair of the Public Policy Committee at ISSCR and Director of Children’s Research Institute at UT Southwestern. He was also President of ISSCR in 2015-2016, and during his tenure I interviewed him here on The Niche about the challenges and future of the stem cell/regenerative medicine field. You can read more about the Morrison lab …Read More

3 min read

It’s notable how the FDA now considers gene-editing a kind of regenerative medicine. This means that various gene therapy products in development technically qualify as regenerative therapies. Ever since the agency began its rapidly growing regenerative medicine advanced therapy (RMAT) designation program, we’ve seen an increasing number of gene therapy biotechs and products qualify as RMATs. As a result, the RMAT-qualified gene therapies get to go into a speedier lane of FDA oversight. Today’s post is a mix of recommended reads in the regenerative …Read More